Virtici - Javelin Oncology, Inc.

aclys

Aclys Bio discovers and develops precision biologics for the treatment of cancer. Aclys has identified a set of novel precision and immune-oncology targets from the tumor molecular profiles of tens of thousands of cancer patients and is building antibody-based therapies against each target, both for internal development, and for partnership. Aclys’s Precision ImmunoLogical Antibody™ discovery platform (PILA™ or PILA Platform™) enables Aclys’s rapid antibody engineering and optimization. The resultant new class of developable precision biologics has unique potential to decrease clinical trial times, costs, and risk, while improving trial success rates and ultimately, patient lives.

Innovation Space: Oncology

Rise Therapeutics Announces FDA Clearance of its IND Application to Initiate a Phase 1 Study of an Oral Immunotherapy for the Treatment of Ulcerative Colitis

Rockville, Maryland, January 31^st, 2023 – Rise Therapeutics, a biopharmaceutical company engaged in developing novel oral synthetic biology medicines, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application to proceed with a Phase 1 clinical trial of its lead program candidate, R-3750.

Nov 14, 2022

Celdara Medical Receives Funding to Develop Broad-Spectrum Antimicrobials for Chronic Lung Infection

Lebanon, NH: The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) has awarded Celdara Medical, LLC a Phase I Small Business Innovation Research (SBIR) grant for development of broad-spectrum antimicrobial peptides to combat chronic lung infection in patients with cystic fibrosis (CF).

Oct 05, 2022

Virtici Announces Funding from NIH to Develop a New Treatment for Periodontal Disease

Seattle, Washington - Virtici LLC announced today that the National Institute of Dental and Craniofacial Research (NIDCR) of the National Institutes of Health (NIH) has awarded a Small Business Innovation Research (SBIR) award to advance VTC-886, a first-in-class small molecule for the prevention of P. gingivalis infection.

Jan 21, 2022

Rise Therapeutics Begins Operations of its GMP Manufacturing Facility

Rockville, MD. Rise Therapeutics announced today that they have successfully initiated operations of their GMP manufacturing facility based in Rockville, MD. Funding to help set up this GMP manufacturing operation came from the National Institute of Health (NIH) Commercialization Readiness Pilot (CRP) Program Grant, which assists small businesses with technical assistance and late-stage development projects that are not typically supported by SBIR and STTR Phase II and Phase IIB grants. Launching of operations for this facility was also supported by the financial contributions of the Montgomery County Economic Development Corporation.

Jan 17, 2022

Aclys Bio and Genmab Enter Research and Commercial License Option Agreement to Develop Proprietary Aclys Antibodies Against an Undisclosed Target

Aclys Bio Corp (“Aclys”), a company discovering and developing precision biologics for the treatment of cancer, earlier this month announced a new exclusive research and commercial license option agreement with Genmab A/S (Nasdaq: GMAB), an international biotech company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.

Sep 01, 2021

Rise Therapeutics Announces Publication of an Important Peer-Reviewed Journal Article Related to its R-3750 Program

Rockville, MD. Rise Therapeutics, a biotechnology company developing first-in-class targeted immunological-based biologics using a unique and proprietary oral delivery platform, announced today the publication of the co-authored article, “Lactococcus lactis Delivery of Surface Layer Protein A Protects Mice from Colitis by Re-Setting Host Immune Repertoire” in the journal Biomedicines.

Ecosystem Startup